Key Highlights

  • FDA Priority Review: The agency accepted uniQure's BLA for ifezuntirgene inilparvovec for Huntington's disease and granted Priority Review status.
  • PDUFA Date Set: The FDA has set a target action date of May 1, 2027 under the Prescription Drug User Fee Act.
  • First-in-Class Potential: If approved, the therapy could become the world's first disease-modifying treatment for Huntington's disease.
  • Confirmatory Trial Underway: Patient screening for the confirmatory study is expected to begin before year-end 2026, enrolling approximately 200 patients.

uniQure N.V.(NASDAQ:QURE), a gene therapy company based in Lexington, Massachusetts, and Amsterdam, reached a landmark milestone when the U.S. Food and Drug Administration accepted for review its Biologics License Application for ifezuntirgene inilparvovec, an investigational gene therapy targeting Huntington's disease. The application was filed under the Accelerated Approval pathway and has been granted Priority Review status, with a PDUFA target action date of May 1, 2027.

The BLA Submission and What Drives It

The application rests on 36-month data from uniQure's Phase I/II clinical studies of ifezuntirgene inilparvovec, analyzed against a propensity score-matched external control cohort drawn from the Enroll-HD natural history database — one of the most comprehensive longitudinal registries for Huntington's disease patients worldwide. The FDA's acceptance of the BLA means the agency has determined the application is sufficiently complete to begin its substantive review.

In its acceptance letter, the FDA indicated it is tentatively planning to convene an Advisory Committee meeting to discuss the application, though the specific date and timeline have not yet been finalized. Advisory Committee meetings introduce an additional layer of scientific deliberation by independent experts before the FDA reaches its decision, and while they are not binding, they often foreshadow the agency's thinking on complex or novel applications.

Ifezuntirgene inilparvovec has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations from the FDA — a trio of regulatory recognition that reflects both the severity of the disease and the agency's assessment of the therapy's potential. No disease-modifying treatment currently exists for Huntington's disease, which is a fatal, inherited neurodegenerative disorder caused by a mutation in the huntingtin gene.

The Therapy and Its Mechanism

The investigational therapy operates through uniQure's proprietary miQURE gene-silencing platform. It incorporates a microRNA specifically engineered to suppress the huntingtin gene and a toxic protein fragment implicated in neuronal damage. Patients receive the therapy through a single administration delivered directly into the striatum — the brain region most affected by Huntington's disease — via MRI-guided, convection-enhanced stereotactic neurosurgery. The one-time delivery approach distinguishes this therapy from treatments that require repeated dosing.

Two multi-center Phase I/II studies evaluated the therapy's safety, tolerability, and efficacy. The 36-month dataset submitted with the BLA provides the evidence base for Accelerated Approval consideration, with Total Functional Capacity serving as the primary endpoint for the confirmatory study.

Risks

Gene therapies delivered by surgical means carry procedural risks beyond those typically associated with systemic biologic therapies. The neurosurgical delivery of ifezuntirgene inilparvovec requires specialized centers and experienced surgical teams, which may limit how widely the therapy can be deployed even if approved. The Accelerated Approval pathway — under which this BLA was submitted — requires a confirmatory trial to verify clinical benefit; failure to demonstrate that benefit in the confirmatory study could lead to the FDA withdrawing approval.

Additionally, Advisory Committee proceedings can be unpredictable, and mixed panel votes have in some cases created uncertainty ahead of final FDA decisions. The Huntington's disease patient population is relatively small, which could affect Revenue trajectories if the therapy reaches market.

What to Watch Next

The most immediate watch item is the scheduling of the Advisory Committee meeting, which the FDA indicated is being tentatively planned. Once a date is confirmed, that meeting will draw significant attention from the scientific community and patient advocates. Patient screening for the confirmatory trial is expected to begin in the United States before year-end 2026, meaning enrollment progress will be another metric to track as the May 2027 PDUFA date approaches.

Any FDA requests for additional information — known as a Complete Response Letter — or any shift in the PDUFA timeline would also be significant news for the company and for Huntington's disease families waiting on a treatment.

Sector Context

Huntington's disease has long been considered one of the most difficult targets in neurodegeneration. Unlike Alzheimer's or Parkinson's, which are typically multifactorial, Huntington's is caused by a single genetic mutation, making it theoretically more amenable to targeted gene-silencing approaches. Yet the challenge of safely delivering a therapeutic payload to specific brain structures has historically limited the field.

uniQure's advancing application represents the culmination of years of Investment in gene silencing and surgical delivery techniques. The broader gene therapy sector has faced a mixed regulatory record, with some approvals in blood disorders and rare pediatric diseases but persistent challenges in neurology. A successful outcome for this BLA would carry implications well beyond Huntington's disease, potentially validating the miQURE platform and CNS gene delivery approach for other neurological targets.